Skip to main content

Numeral Limited (XII.JO)

JNB Healthcare Medical - PharmaceuticalsView data quality →
55.4Fair

ValueMarkers Composite Index

Top 55%#20,029 of 44,722
Undervalued

100% below intrinsic value ($34,674)

UndervaluedFair ValueOvervalued
Piotroski
2/9
Weak
Beneish
-10.00
Low Risk
Altman
-11.95
Distress
DCF Value
$34,674
Undervalued
ROIC
14.2%
Adequate
P/E
0.3
Value
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Numeral Limited (XII.JO) — VMCI valuation read

Headline read on XII.JO: VMCI of 55/100 versus a Healthcare sector median of 50. The 5-point above-median position is what makes Numeral Limited a relative-value candidate in the mid-cap cohort, before any pillar-level review.

Form 4 filings on XII.JO: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on XII.JO: value (XII.JO trades at 17.0x earnings, 6% below the Healthcare median of 18.0x), quality (ROIC of 15.0% sits 5.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 1.3x leaves covenant headroom). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

XII.JO fell 2.7% over the trailing 7 days, with a -6.9% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.